MedTrace Logo

RAAS Inhibitor Drugs in Dialysis Patients

NCT01635387 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2012-07-09

No results posted yet for this study

Summary

Hypertensive haemodialysis patients are at high risk for cardiovascular events. This study was undertaken to ascertain whether the upstream of aliskirne, a direct renin inhibitor improves mortality and cardiovascular outcomes in these high-risk population.

Conditions

Interventions

DRUG

aliskiren

150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated

Sponsors & Collaborators

  • IRCCS San Raffaele

    collaborator OTHER

  • University of Campania Luigi Vanvitelli

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2012-09-30
Completion
2012-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01635387 on ClinicalTrials.gov